Physician

Nadia Khan, MD

According to 2025 Medicare claims, Nadia Khan, MD (NPI: 1659531499) practices hematopoietic cell transplantation and cellular therapy in the Chicago-Naperville-Schaumburg, IL market, with the plurality of this provider's patient population coming from Cook, IL. This provider's primary affiliated billing organization is RUSH UNIVERSITY MEDICAL GROUP (NPI: 1093819542; TIN: 91-1780160) and primary practice location at 60607-3106. Khan is affiliated with the Health Connect Partners, LLC (ACO ID: A2342) and Jefferson Accountable Care, LLC (ACO ID: A5275), participating under the MSSP model.

Khan's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 118 traditional Medicare patients, billed 207 HCPCS/CPT codes, and received $19,235 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 430 prescription claims across 66 beneficiaries totaling $2,688,034 in drug costs, led by Calquence (Acalabrutinib Maleate). Open Payments data shows 31 records totaling $446,388. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has fallen sharply in recent years, from $31,648 to $19,235. In contrast, Part D prescription costs have risen steadily, from $309,882 to $2,688,034. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	117	360	$31,648
2016	133	508	$45,737
2017	162	525	$45,737
2018	172	493	$42,894
2019	266	835	$63,744
2020	245	661	$47,323
2021	240	607	$56,097
2022	207	348	$31,173
2023	108	238	$22,887
2024	118	207	$19,235

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	52	278	$309,882
2016	62	477	$832,571
2017	73	553	$1,171,383
2018	59	362	$1,074,146
2019	69	249	$536,023
2020	73	414	$1,359,237
2021	60	279	$1,572,650
2022	57	215	$1,041,356
2023	66	325	$1,796,049
2024	66	430	$2,688,034

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	15	15	$153
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	17	17	$112
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	44	67	$111
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	58	72	$71
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	11	12	$52

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Calquence	Acalabrutinib Maleate	73	2,190	$1,053,940
Venclexta	Venetoclax	69	2,030	$933,483
Brukinsa	Zanubrutinib	29	870	$364,972
Jaypirca	Pirtobrutinib	11	330	$247,398
Eliquis	Apixaban	13	375	$7,188

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	3	$62	Stemline Therapeutics Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	28	$446,326	Eli Lilly and Company
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Nadia Khan, MD?

Tedicare shows public-source Medicare data for Nadia Khan, MD (NPI 1659531499), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Nadia Khan, MD have ACO affiliation data?

Nadia Khan, MD is shown with ACO affiliation data for Health Connect Partners, LLC (MSSP, ACO ID A2342) and Jefferson Accountable Care, LLC (MSSP, ACO ID A5275).

What billing organization is linked to Nadia Khan, MD?

Nadia Khan, MD is linked to RUSH UNIVERSITY MEDICAL GROUP (billing NPI 1093819542) in the available physician profile data.

Does Nadia Khan, MD have Open Payments data?

Nadia Khan, MD has 31 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.